Hal Barron has said farewell after a four-and-a-half year stint as GSK’s chief scientific officer, leaving behind what he and CEO Dame Emma Walmsley argue is a much more competitive and innovation-driven organization – but conceded that the transformation was far from complete.
Barron is leaving the post to become CEO of the ambitious cellular reprogramming venture Altos Labs, and hands over...